Annual report pursuant to Section 13 and 15(d)

License, Collaborative and Employment Agreements and Commitments - Additional Information (Details)

v3.20.4
License, Collaborative and Employment Agreements and Commitments - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Dec. 30, 2020
Aug. 07, 2019
Sep. 05, 2018
Sep. 05, 2018
Aug. 31, 2015
Aug. 29, 2015
Aug. 10, 2015
Dec. 05, 2013
Dec. 05, 2013
Oct. 05, 2012
Nov. 30, 2017
Dec. 19, 2012
Dec. 19, 2012
Nov. 28, 2012
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2015
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Payments for Other Fees                     $ 4,500,000            
Exchange percentage of unregistered common stock               50.00% 50.00%                
Proceeds from (Repurchase of) Equity                 $ 3,000,000                
Options To Be Received Common Stock Shares                             2,000,000    
Milestone Payment upon First Dosing       $ 3,000,000                     $ 3,000,000    
Fair Value Of Shares Issued     $ 285,000                            
Operating Lease, Cost                             209,000 $ 201,000  
Operating Lease, Payments                             $ 309,000 300,000  
Operating Lease, Weighted Average Discount Rate, Percent                             9.90%    
Research and Development Expense     $ 198,000                       $ 5,131,000 11,083,000  
SYN Biomics [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Additional Number Of Common Stock To Be Issued     2,420,000 2,420,000                          
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners                             17.00%    
Cedarssinai Medical Center [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Percentage Of Common Stock Outstanding                 11.50%                
Payments to Acquire in Process Research and Development     $ 441,000                            
Number Of Common Stock To Be Issued     50,000 50,000                          
Number Of Common Stock To Be Held By Related Party     7,480,000 7,480,000                          
Cedarssinai Medical Center [Member] | SYN Biomics [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Additional Number Of Common Stock To Be Issued     2,420,000 2,420,000                          
Mark Pimentel M.D [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Percentage Of Common Stock Outstanding                 8.50%                
Licensing Agreements [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Annual payments due under license agreement                       $ 50,000          
Final payment due under license agreement                       25,000          
Payments for Other Fees               $ 150,000                  
Stock Issued During Period, Shares, New Issues               9,569                  
Patents [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Payments for Other Fees               $ 220,000                  
Steven A. Shallcross [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage 62.00%                                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 450,000                                
Intrexon [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Stock Issued During Period, Shares, Acquisitions                   101,492              
Shares Issued, Price Per Share                   $ 0.001              
Milestone Payment upon First Dosing             $ 2,000,000               $ 2,000,000    
Prev Abr Llc [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Additional Cash Payment for License Agreement                           $ 235,000      
Unregistered Shares Issued to License Agreement                           17,858      
Additional Consideration Payable                           50% in cash and 50% in our stock      
Options To Be Received Common Stock Shares                                 18,724
Phase I Clinical Trials [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Milestone Payment                         $ 50,000        
Phase III Clinical Trials [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Milestone Payment                         100,000        
NDA Submission In US [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Milestone Payment                         250,000        
European Medicines Agency Approval [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Milestone Payment                         100,000        
Regulatory Approval In Asian Country [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Milestone Payment                         100,000        
PKU ECC [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Shares, Issued             26,786                    
Stock Issued             $ 3,000,000                    
Stock Purchase Agreement [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Conversion of Stock, Shares Converted           38,572                      
Conversion of Stock, Shares Issued         38,572                        
Research and Development Expense       $ 225,000                     $ 225,000 $ 198,000  
Clinical Trial Agreement [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Estimated Research Costs   $ 3,200,000                              
First Year [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Research Agreement Fixed Fee                       303,287 303,287        
Second Year [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Research Agreement Fixed Fee                       316,438 316,438        
Third Year [Member]                                  
License, Collaborative and Employment Agreements and Commitments [Line Items]                                  
Research Agreement Fixed Fee                       $ 328,758 $ 328,758